#122 Why AI Drug Discovery Is So Hard — Dr Imran Haque (Recursion) - a podcast by Mustafa Sultan

Despite $billions of investment into the sector — there are still no AI discovered drugs on the market. Why?

Recursion Pharmaceuticals (NASDAQ: RXRX) is one of the hottest AI drug discovery companies on the market. Especially after NVIDIA's $50M investment into them.

Dr Imran Haque (SVP of AI and Digital Sciences) explains why AI drug discovery is so tricky — and when it's arriving.

0:00 Intro
0:42 Decoding biology (the big idea)
2:18 Why is AI drug discovery harder than it looks?
4:48 Simulating the Sims (game) vs AI drug discovery
6:58 Building data for AI drug discovery
14:47 Recursion's successes and failures
24:22 The barriers to AI drug discovery
26:45 How optimistic should we be about AI drug discovery
35:26 Being aggressively generalist for success

People
Dr Imran Haque: https://www.recursion.com/team-members/imran-haque
Dr Imran Mahmud: https://www.imranmahmud.com/
Dr Mustafa Sultan: https://www.musty.io/

Further episodes of Big Picture Medicine

Further podcasts by Mustafa Sultan

Website of Mustafa Sultan